On August 25, 2025, ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco, announced publication of positive long-term safety and efficacy data for givinostat as a treatment for Duchenne muscular dystrophy (DMD) from the company’s open-label extensions of its Phase 2 and Phase 3 (EPIDYS) trials.
To view all details in their full announcement, please click here.
